Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations

被引:23
|
作者
Le, V. N. P. [1 ,2 ]
Robins, E. [3 ]
Flament, M. P. [1 ,2 ]
机构
[1] Univ Lille Nord France, Coll Pharm, Lille, France
[2] INSERM U 1008, Lille, France
[3] APTAR Pharma, F-27100 Le Vaudreuil, France
关键词
Gas permeation; DPI performance; Fluticasone; Agglomerates; Powder aerosolisation; IN-VITRO DEPOSITION; SALMETEROL XINAFOATE; LACTOSE CARRIER; PARTICLE-SIZE; RESPIRABLE PARTICLES; AEROSOL DISPERSION; SURFACE-PROPERTIES; DRUG; INHALATION; MIXTURES;
D O I
10.1016/j.ejpb.2011.12.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Due to their small size, the respirable drug particles tend to form agglomerates which prevent flowing and aerosolisation. A carrier is used to be mixed with drug in one hand to facilitate the powder flow during manufacturing, in other hand to help the fluidisation upon patient inhalation. Depending on drug concentration, drug agglomerates can be formed in the mixture. The aim of this work was to study the agglomeration behaviour of fluticasone propionate (FP) within interactive mixtures for inhalation. The agglomerate phenomenon of fluticasone propionate after mixing with different fractions of lactose without fine particles of lactose (smaller than 32 pm) was demonstrated by the optical microscopy observation. A technique measuring the FP size in the mixture was developed, based on laser diffraction method. The FP agglomerate sizes were found to be in a linear correlation with the pore size of the carrier powder bed (R-2 = 0.9382). The latter depends on the particle size distribution of carrier. This founding can explain the role of carrier size in de-agglomeration of drug particles in the mixture. Furthermore, it gives more structural information of interactive mixture for inhalation that can be used in the investigation of aerosolisation mechanism of powder. According to the manufacturing history, different batches of FP show different agglomeration intensities which can be detected by Spraytec (R), a new laser diffraction method for measuring aerodynamic size. After mixing with a carrier, Lactohale LH200, the most cohesive batch of FP, generates a lower fine particle fraction. It can be explained by the fact that agglomerates of fluticasone propionate with very large size was detected in the mixtures. By using silica-gel beads as ball-milling agent during the mixing process, the FP agglomerate size decreases accordingly to the quantity of mixing aid. The homogeneity and the aerodynamic performance of the mixtures are improved. The mixing aid based on ball-milling effect could be used to ameliorate the quality of inhalation mixture of cohesive drug, such as fluticasone propionate. However, there is a threshold where an optimal amount of mixing aids should be used. Not only the drug des-aggregation reaches its peak but the increase in drug-carrier adhesion due to high energy input should balance the de-agglomeration capacity of mixing process. This approach provides a potential alternative in DPI formulation processing. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:596 / 603
页数:8
相关论文
共 50 条
  • [41] Fluticasone furoate/vilanterol dry-powder inhaler: a guide to its use in chronic obstructive pulmonary disease
    McKeage K.
    Drugs & Therapy Perspectives, 2015, 31 (4) : 112 - 117
  • [42] Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects
    Kirjavainen, Merja
    Mattila, Leena
    Vahteristo, Mikko
    Korhonen, Jani
    Lahelma, Satu
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2018, 31 (05) : 290 - 297
  • [43] Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation
    He, Xianhong
    Li, Jiayi
    Wen, Xiangce
    Ma, Sibo
    An, Yalin
    Zhang, Xin
    Guan, Jian
    Mao, Shirui
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 664
  • [44] HPLC Method for Simultaneous Determination of Salmeterol Xinafoate and Fluticasone Propionate for the Quality Control of Dry Powder Inhalation Products
    Paczkowska, E.
    Smukowska, D.
    Tratkiewicz, E.
    Bialasiewicz, P.
    ACTA CHROMATOGRAPHICA, 2015, 27 (02) : 309 - 320
  • [45] NANOLIPOSOMAL DRY POWDER FORMULATIONS
    Patel, Gaurang
    Chougule, Mahavir
    Singh, Mandip
    Misra, Ambikanandan
    METHODS IN ENZYMOLOGY; LIPOSOMES, PT F, 2009, 464 : 167 - +
  • [46] Rational design of a dry powder inhaler: device design and optimisation
    Friebel, Christian
    Steckel, Hartwig
    Mueller, Bernd W.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (09) : 1303 - 1315
  • [47] Experimental investigation of design parameters on dry powder inhaler performance
    Nguyen Thi Quynh Ngoc
    Chang, Lusi
    Jia, Xinli
    Lau, Raymond
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 457 (01) : 92 - 100
  • [48] Dry powder inhaler device influence on carrier particle performance
    Donovan, Martin J.
    Kim, Sin Hyen
    Raman, Venkatramanan
    Smyth, Hugh D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (03) : 1097 - 1107
  • [49] Particle Interactions in Dry Powder Inhaler Unit Processes: A Review
    Xu, Zhen
    Mansour, Heidi M.
    Hickey, Anthony J.
    JOURNAL OF ADHESION SCIENCE AND TECHNOLOGY, 2011, 25 (4-5) : 451 - 482
  • [50] Nano- and Microstructured model carrier surfaces to alter dry powder inhaler performance
    Renner, Niklas
    Steckel, Hartwig
    Urbanetz, Nora
    Scherliess, Regina
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 518 (1-2) : 20 - 28